Welcome to the e-CCO Library!

P540: Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Yamamoto T.*1, Tanaka T.2, Yokoyama T.3, Shimoyama T.1, Ikeuchi H.4, Uchino M.4, Watanabe T.2

Created: Wednesday, 20 February 2019, 10:36 AM
P540: Longitudinal Dynamics of Gut Microbiome and Metabolome After Biological Therapy in Inflammatory Bowel Diseases
Year: 2022
Source: ECCO'22
Authors: Ahmed, M.(1);Metwaly, A.(1);Hammoudi, N.(2);Meng, C.(3);Köhler, N.(4);Le Bourhis, L.(2);Pauling, J.(4);Kleigrewe, K.(3);Allez, M.(2);Haller, D.(1);
Created: Friday, 11 February 2022, 3:56 PM
P540: Real-world evidence on treatment switching in patients with moderate-to-severe ulcerative colitis: a systematic review of literature
Year: 2021
Source: ECCO'21 Virtual
Authors: Singh, H.(1);Wilson, L.(2);Pandey, A.(3);Tencer, T.(4);Kumar, J.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P540: The opinions and needs of patients living with refractory ulcerative proctitis, and the health care professionals who care for them; A Delphi consensus survey
Year: 2023
Source: ECCO’23 Copenhagen
Authors: RadfordBSc- MSc- PGCert- PhD student, S.(1)*;Kyriacou, M.(2);Moran, G.(3);
Created: Friday, 14 July 2023, 11:05 AM
P540: Therapeutic drug monitoring in ustekinumab: which factors affect trough levels?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Theeuwen*1, N. Provoost1, M. Koning1, A. Van der Meulen - de Jong1, D. J. A. Moes2, J. Maljaars1

Created: Friday, 22 February 2019, 9:41 AM
P541 Are we addressing the top ten research priorities in IBD?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Geldof1, J.F. LeBlanc1, L. Lucaciu2, J.P. Segal1, C.W. Lees2, A. Hart1

Created: Thursday, 30 January 2020, 10:12 AM
P541: Clinical factors associated with discontinuation of combo or monotherapy for Crohn’s disease: A sub-analysis of a prospective randomised clinical trial (DIAMOND study)
Year: 2018
Source: ECCO '18 Vienna
Authors:

T. Hisamatsu1*, T. Matsumoto2, K. Watanabe3, H. Nakase4, S. Motoya5, N. Yoshimura6, T. Ishida7, S. Kato8, T. Nakagawa9, M. Esaki10, M. Nagahori11, T. Matsui12, Y. Naito13, T. Kanai14, Y. Suzuki15, M. Nojima16, M. Watanabe17, T. Hibi18, DIAMOND study group1

Created: Thursday, 21 February 2019, 9:14 AM
P541: Diagnosis, management, and evolution of acute pancreatitis secondary to thiopurines in patients with Inflammatory Bowel Disease: an ENEIDA registry study.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Guerra Marina, I.(1)*;Barros, F.(2);Mesonero, F.(3);de Francisco, R.(4);Cañete, F.(5,6);Benítez, J.M.(7);Sicilia, B.(8);Martín Arranz, M.D.(9);de Castro, L.(10);Carbajo, A.Y.(11);Gutiérrez, A.(6,12);Calvo, M.(13);Casanova, M.J.(6,14);González-Muñoza, C.(15);Miguel, M.(16);Alfambra, E.(6,17);Rivero, M.(18);Lucendo, A.J.(6,19);Tardillo, C.A.(20);Almela, P.(21);Bujanda, L.(6,22);Van Domselaar, M.(23);Ramos, L.(24);Fernández Sánchez, M.(25);Hinojosa, E.(26);Verdejo, C.(27);Gimenez, A.(28);Piqueras, M.(29);Rodríguez-Lago, I.(30);Manceñido, N.(31);Pérez Calle, J.L.(32);Moreno, M.D.P.(33);Delgado, P.G.(34);Antolín, B.(35);Ramírez de la Piscina, P.(36);Bermejo, F.(37);Carracedo, Á.(38);Domènech, E.(5,6);Gisbert, J.P.(6,14);
Created: Friday, 14 July 2023, 11:05 AM
P541: Effectiveness, safety and durability of vedolizumab in active moderate-severe Crohn's Disease
Year: 2022
Source: ECCO'22
Authors: Morales Bermúdez, A.I.(1);Bracho González, M.(1);Gómez Rodríguez, P.(1);Olmedo Martín, R.(1);
Created: Friday, 11 February 2022, 3:56 PM
P541: Efficacy, efficiency and aceptability of telemedicine for inflammatory bowel disease patients follow-up care during the COVID-19 pandemic lockdown.
Year: 2021
Source: ECCO'21 Virtual
Authors: Ramos Lopez, L.(1);Reygosa, C.(1);Carrillo-Palau, M.(1);Alonso-Abreu, I.(1);González, Y.(1);de la Barreda, R.(1);Amaral , C.(1);Hernández, A.(1);Benítez-Zafra, F.(1);Hernández-Guerra, M.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P541: Intestinal failure: a rare but significant outcome of restorative proctocolectomy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Segal J., Oke S., Clark S., Hart A.

Created: Wednesday, 20 February 2019, 10:36 AM
P541: Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: an IG-IBD study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

D. Pugliese*1, M. Daperno2, G. Fiorino3, E. Savarino4, E. Mosso5, L. Biancone6, A. Testa7, L. Sarpi8, M. Cappello9, G. Bodini10, F. Caprioli11, S. Festa12, G. Laino13, G. Maconi14, S. Mazzuoli15, G. Mocci16, A. Sartini17, A. D'Amore18, S. Alivernini19, E. Gremese19, A. Armuzzi20

Created: Friday, 22 February 2019, 9:41 AM
P542 The effect of age on infliximab pharmacokinetics in patients with inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

W. Kantasiripitak1, B. Verstockt2,3, T. Lobatón2,3,4, D. Thomas1, A. Gils1, S. Vermeire2,3, M. Ferrante2,3, E. Dreesen1

Created: Thursday, 30 January 2020, 10:12 AM
P542: Clinical presentation, disease behavior and management of inflammatory bowel disease at extremes of age
Year: 2021
Source: ECCO'21 Virtual
Authors: Bhangale, N.(1);Desai, D.C.(1);Abraham, P.(1);Gupta, T.(1);Dhoble, P.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P542: Efficacy and safety of biological therapies in chronic antibiotic-refractory pouchitis: a retrospective single-centre experience
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. Verstockt*1,2, C. Claeys1, G. Van Assche1,2, A. D'Hoore3, A. Wolthuis3, S. Vermeire1,2, M. Ferrante1,2

Created: Friday, 22 February 2019, 9:41 AM
P542: Infliximab salvage therapy in acute severe ulcerative colitis: A systematic review and meta-analysis
Year: 2018
Source: ECCO '18 Vienna
Authors:

M.C. Choy1,2,3*, D. Seah1, D.M. Faleck4, S.C. Shah4, A. Al-Khoury5, Y.-K. An6, G. Radford-Smith6, T. Bessissow5, A.C. Ford7,8, M. Dubinksy4, N. Yeomans2, P. De Cruz1,2

Created: Thursday, 21 February 2019, 9:14 AM
P542: Short term efficacy, safety and thromboembolic risk of tofacitinib in moderate to severe Ulcerative Colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Cingolani, L.(1);Barberio, B.(1)*;Zelante, A.(2);Ribaldone, D.(3);Testa, G.(3);Bertani, L.(4);Buda, A.(5);Zingone, F.(1);Savarino, E.V.(1);
Created: Friday, 14 July 2023, 11:05 AM
P542: Topical tacrolimus versus systemic biological therapy for refractory ulcerative proctitis: a retrospective cohort study
Year: 2022
Source: ECCO'22
Authors: Crispino, F.(1);Michielan, A.(2);Tieppo, C.(2);Mazza, M.(2);Rogger, T.M.(2);Brinch, D.(1);Cappello, M.(1);Armelao, F.(2);
Created: Friday, 11 February 2022, 3:56 PM
P543 UC remission mucosa displays upregulated inflammatory mediators
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Arkteg1, R. Goll2, M. Dixon Gundersen1, E. Anderssen1, C.G. Fenton1, J. Florholmen2

Created: Thursday, 30 January 2020, 10:12 AM